PMID- 36751548
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230209
IS  - 1642-395X (Print)
IS  - 2299-0046 (Electronic)
IS  - 1642-395X (Linking)
VI  - 38
IP  - 2
DP  - 2021 Apr
TI  - Efficacy, quality of life, and safety of methotrexate versus interferon in 
      head-to-head treatment in advanced stages of mycosis fungoides and Sezary 
      syndrome. Prospective trial (NCT02323659).
PG  - 295-301
LID - 10.5114/ada.2021.106206 [doi]
AB  - INTRODUCTION: ESMO guidelines recommend interferon (IFN) and methotrexate (MTX) 
      as first-line systemic therapies in mycosis fungoides (MF) and Sezary syndrome 
      (SS). AIM: A prospective, head-to-head trial comparing the efficacy and safety of 
      INF-alpha and MTX as first-line treatment in MF/SS patients. MATERIAL AND METHODS: 
      Forty-three patients were enrolled in the trial. The response to treatment and 
      side effects were assessed. Study variables included mSWAT, DLQI, and VAS scores. 
      RESULTS: The response rate in stage IV including SS was significantly higher in 
      the IFN-alpha group than in the MTX group (100% vs. 40%; p = 0.03, respectively). No 
      significant differences were found in response rate in stage IIB and III between 
      treatment groups. Patients treated with IFN-alpha had significantly shorter time to 
      achieve response (TTR). Significantly fewer in the IFN-alpha group experienced 
      adverse events (AE) in comparison to patients treated with MTX (81% vs. 45%; p = 
      0.02). There was no statistically significant difference between both groups in 
      terms of time to progression (TTP), progression-free survival (PFS), time on 
      treatment (ToT), and time to next treatment (TTNT). The improvement in quality of 
      life and reduction of pruritus was comparable in both treatment groups. 
      CONCLUSIONS: The obtained data suggest that the efficacy of IFN-alpha as first-line 
      treatment in advanced stage (IV) MF and SS is significantly better than MTX. 
      IFN-alpha presented significantly better safety and tolerability and shorter TTR than 
      MTX. However, the results should be interpreted with caution due to scarce study 
      groups.
CI  - Copyright (c) 2022 Termedia.
FAU - Chmielowska, Ewa
AU  - Chmielowska E
AD  - Bydgoszcz Cancer Centre, Bydgoszcz, Poland.
AD  - Centre for Diagnostics and Oncology Therapy, Tomaszow Mazowiecki, Poland.
AD  - Polish Lymphoma Research Group (PLRG).
FAU - Sokolowska-Wojdylo, Malgorzata
AU  - Sokolowska-Wojdylo M
AD  - Polish Lymphoma Research Group (PLRG).
AD  - Department of Dermatology, Venerology and Allergology, Faculty of Medicine, 
      Medical University of Gdansk, Gdansk, Poland.
FAU - Olszewska, Berenika
AU  - Olszewska B
AD  - Department of Dermatology, Venerology and Allergology, Faculty of Medicine, 
      Medical University of Gdansk, Gdansk, Poland.
FAU - Studzinski, Maciej
AU  - Studzinski M
AD  - Hospital "Elbl(1)ska" Luxmed, Warsaw, Poland.
FAU - Grzanka-Gadzinska, Aleksandra
AU  - Grzanka-Gadzinska A
AD  - Polish Lymphoma Research Group (PLRG).
AD  - Nicolaus Copernicus University in Torun, Ludwik Rydygier Medical College in 
      Bydgoszcz, Poland.
FAU - Zablotna, Monika
AU  - Zablotna M
AD  - Department of Dermatology, Venerology and Allergology, Faculty of Medicine, 
      Medical University of Gdansk, Gdansk, Poland.
FAU - Olek-Hrab, Karolina
AU  - Olek-Hrab K
AD  - Department of Dermatology, Sexually Transmitted Diseases and Immunodermatology, 
      Poznan University of Medical Sciences, Poznan, Poland.
FAU - Iwanowski, Tomasz
AU  - Iwanowski T
AD  - Dermedica, Gdynia, Poland.
FAU - Olejniczak, Monika
AU  - Olejniczak M
AD  - Bydgoszcz Cancer Centre, Bydgoszcz, Poland.
AD  - Centre for Diagnostics and Oncology Therapy, Tomaszow Mazowiecki, Poland.
FAU - Krause, Anna
AU  - Krause A
AD  - Bydgoszcz Cancer Centre, Bydgoszcz, Poland.
AD  - Centre for Diagnostics and Oncology Therapy, Tomaszow Mazowiecki, Poland.
FAU - Giebel, Sebastian
AU  - Giebel S
AD  - Polish Lymphoma Research Group (PLRG).
AD  - Department of Bone Marrow Transplantation and Oncohaematology, Maria 
      Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Gliwice, 
      Poland.
LA  - eng
PT  - Journal Article
DEP - 20210522
PL  - Poland
TA  - Postepy Dermatol Alergol
JT  - Postepy dermatologii i alergologii
JID - 101168357
PMC - PMC9880780
OTO - NOTNLM
OT  - cutaneous T-cell lymphoma
OT  - efficacy
OT  - interferon
OT  - methotrexate
COIS- The authors declare no conflict of interest.
EDAT- 2021/04/01 00:00
MHDA- 2021/04/01 00:01
PMCR- 2021/04/01
CRDT- 2023/02/08 01:58
PHST- 2020/09/07 00:00 [received]
PHST- 2020/09/15 00:00 [accepted]
PHST- 2023/02/08 01:58 [entrez]
PHST- 2021/04/01 00:00 [pubmed]
PHST- 2021/04/01 00:01 [medline]
PHST- 2021/04/01 00:00 [pmc-release]
AID - 44102 [pii]
AID - 10.5114/ada.2021.106206 [doi]
PST - ppublish
SO  - Postepy Dermatol Alergol. 2021 Apr;38(2):295-301. doi: 10.5114/ada.2021.106206. 
      Epub 2021 May 22.